EUVIMEDEUVIMED entdecken
Fallbericht

PRAME ‐Positive Eruptive Melanocytic Nevi in the Setting of BRAF ‐Inhibitors

Maxine M Mackie iD, Sameera Husain, Alejandro A Gru, Stephanie M Gallitano

Journal of Cutaneous Pathology · 2026

DOI: 10.1111/cup.70111 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Journal of Cutaneous Pathology, 2026. Verfasst von Maxine M Mackie und 3 weiteren Autor:innen. Beteiligte Einrichtung: Columbia Vagelos College of Physicians and Surgeons, Columbia University, New York, New York, USA. Hauptthemen laut MEDLINE: Antigens, Neoplasm, Carbamates, Nevus, Pigmented, Proto-Oncogene Proteins B-raf. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 16 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Preferentially Expressed Antigen in Melanoma (PRAME) is an immunohistochemical marker utilized in the diagnosis of melanocytic neoplasms. While still considered highly specific, both diffuse and variable PRAME immunoreactivity have been demonstrated in benign melanocytic lesions. This phenomenon is widely documented, as well as the phenomenon of eruptive melanocytic nevi (EMN) arising in the context of BRAF‐inhibition. We report here a patient on encorafenib who developed numerous new pigmented lesions within 3 weeks of therapy. Initial biopsy suggested evolving melanoma in situ with 70%–75% intraepidermal melanocytes strongly PRAME positive, prompting additional testing. Two subsequent lesions demonstrated only focal PRAME staining and lacked malignant features, leading to the reclassification of the initial lesion as a compound nevus with unusual features. This case underscores that BRAF inhibition may enhance PRAME expression in benign melanocytic nevi, potentially through mechanisms involving mitogen‐activated protein kinase (MAPK) activation, altered Erk phosphorylation, or disruption of retinoic acid (RA) signaling. This case also brings awareness to the potential of medication‐induced PRAME expression and encourages both dermatologists and dermatopathologists to avoid overdiagnosis as PRAME continues to gain prominence as a diagnostic biomarker.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antigens, NeoplasmCarbamatesNevus, PigmentedProto-Oncogene Proteins B-rafSkin NeoplasmsSulfonamidesHumansMaleBiomarkers, TumorMelanocytesMelanomaAged

Stichwörter der Autor:innen

BRAF inhibitionPRAMEencorafeniberuptive melanocytic nevimelanoma

Substanzen

Antigens, NeoplasmBiomarkers, TumorBRAF protein, humanCarbamatesencorafenibPRAME protein, humanProto-Oncogene Proteins B-rafSulfonamides

Autor:innen und Institutionen

  • Columbia Vagelos College of Physicians and Surgeons, Columbia University, New York, New York, USA.
  • Department of Dermatology, Columbia University Irving Medical Center, New York, New York, USA.

ORCID-Profile: Maxine M Mackie

Zitieren

APA

Mackie, M. M., Husain, S., Gru, A. A., & Gallitano, S. M. (2026). PRAME ‐Positive Eruptive Melanocytic Nevi in the Setting of BRAF ‐Inhibitors. Journal of Cutaneous Pathology. https://doi.org/10.1111/cup.70111

Vancouver

Mackie MM, Husain S, Gru AA, Gallitano SM. PRAME ‐Positive Eruptive Melanocytic Nevi in the Setting of BRAF ‐Inhibitors. Journal of Cutaneous Pathology. 2026. doi:10.1111/cup.70111

BibTeX
@article{Mackie2026,
  author = {Mackie, Maxine M and Husain, Sameera and Gru, Alejandro A and Gallitano, Stephanie M},
  title = {PRAME ‐Positive Eruptive Melanocytic Nevi in the Setting of BRAF ‐Inhibitors},
  journal = {Journal of Cutaneous Pathology},
  year = {2026},
  doi = {10.1111/cup.70111}
}
Kostenlos starten →